EMA’s Emergency Task Force (ETF) is engaging with the African Medicines Agency (AMA) and its national regulatory authorities (NRAs), leveraging expertise from the WHO-AFRO African Vaccines Regulatory Forum (AVAREF), to discuss possible clinical trial designs and medical countermeasures to be investigated in the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda, caused by the Bundibugyo virus.

This is the first public health emergency where EMA collaborates with the AMA since it has come into operation, alongside participating African NRAs. This engagement, grounded in the ongoing scientific collaboration between EMA and AMA, is intended to support efficient, coordinated and timely regulatory responses to the outbreak. It also builds on the extensive experience gained through African regulatory collaboration during previous Ebola outbreaks, including joint reviews conducted via AVAREF, as well as the ongoing operationalisation of the AMA.

On 17…